SP-0292: The issue of the quality of data in clinical trials  by Blanchard, P.
S148                                                                                                                                         3rd ESTRO Forum 2015 
 
make comparison of results between different studies 
difficult and standardization is called for.  The quantitative 
imaging biomarker alliance (QIBA) is an example of an 
initiative that aims to improve the value and practicality of 
quantitative imaging biomarkers by reducing variability 
across devices, patients and time. 
Whereas standardization in methodology is important for 
quantification, it has to be able to accommodate emerging 
new techniques. It is untenable to continue using outdated 
methods, simply because earlier studies did not have access 
to more advanced equipment. Therefore, within a 
multicenter project using quantitative MRI for imaging cancer 
in the prostate and cervix, we developed a procedure that 
allows each center to use the optimal sequences for their 
scanner. In a series of phantom and volunteer experiments 
these sequences are benchmarked against well-established 
sequences which are robust, but typically too slow for clinical 
use. Consistent quantification with a bias of a few percent 
between different scanners and institutes was feasible for T2 
mapping, as well as for diffusion-weighted MRI. With newer 
scanners and sequences typically more precise results were 
obtained. This strategy is therefore a way to achieve 
consistency between quantitative results from different 
centers and studies.  
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Clinical trials are considered as the most rigorous way to 
prospectively evaluate the efficacy and toxicity of 
treatments. When randomized designs are used they also 
provide comparative effectiveness between several 
therapies. Good Clinical Practice is the universal ethical and 
scientific quality standard for conducting clinical trials and 
applies to all aspects of the clinical trial process. Quality is 
viewed as a continuum, going from trial design to analysis 
and reporting. The quality of a clinical trial at an investigator 
site is usually assessed by sponsor audits and regulatory 
inspections, but radiation oncology trials can, through RTQA 
procedures, include an innovative means of quality 
assessment which can ultimately generate data and 
hypotheses. The Clinical Trials Transformation Initiative has 
defined quality as “the ability to effectively answer the 
intended question about the benefits and risks of a medical 
product (therapeutic or diagnostic) or procedure, while 
assuring protection of human subjects”. 
The different issues of quality in clinical trials will be 
discussed, including trial design, statistical hypotheses, 
interventions, data recording and monitoring, statistical 
analysis, trial reporting and interpretation. Means to improve 
trials quality and generalization of trials’ results will also be 
discussed. All the limitations to data quality in prospective 
trials described will also apply to other forms of clinical 
research, such as data-mining, and are usually minimized and 
controlled in randomized trials. It is crucial to allow external 
audit and meta-analyses, as these procedures can identify 
and potentially reduce biases. Ultimately the reader is the 
last judge of trial quality through the critical reading of 
medical literature.  
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Aim: ESTRO has formed a task force on risk management 
within radiation oncology (RO).  ESTRO represents all the 
professionals working within RO and is therefore the most 
appropriate partner to work with on issues relating to risk 
and risk management within radiotherapy.  One example is in 
the implementation of the latest EU directive on basic safety 
standard in radiation protection, which will make reporting 
and learning from incidents and near incidents a legal 
requirement.  ESTRO works closely with the National 
Societies in EU and is ideally positioned to inform and advise 
on this and all other related issues. 
Methods: The remit of the working group was to define the 
specific tasks that should be carried out.  These include: 
•       To develop a body of knowledge in order to position 
ESTRO such that they can inform and influence policy with 
respect to risk management in radiotherapy at the level, for 
instance of the European Commission 
•       To prepare and disseminate information to the National 
Societies and the ESTRO community on important 
developments in the area of risk management and incident 
reporting and learning that they should be aware of.   
•       To position ESTRO as an interface with other 
professional bodies such as ASTRO/AAPM to ensure 
consistency of approach internationally.   
•       To liaise between European and global bodies, the 
National Societies and the ESTRO community to advise with 
respect to effective implementation of the new EURATOM 
Directive. 
•       To carry out a scoping exercise of all the current 
activities in the area of risk management and incident 
learning specifically to identify variations and 
inconsistencies. 
 Incident Learning Systems (ILS): 
 •       ROSIS, SAFRON (IAEA) 
 •       RO-ILS (ASTRO/AAPM) 
 •       National Reporting and Learning System – 
NRLS with specific coding for RT (UK) 
 •       Canadian Partneship for Quality in 
Radiotherapy – CPQR (Ca) 
 •       Etc… 
 
Consistent with the requirements of the new EURATOM Basic 
Safety Standards which will mandate new measures in 
relation to risk management in radiotherapy, the ESTRO, as 
the European professional body in radiotherapy should be in a 
position to give direction in relation to (for example): 
What should be considered a mandatory reportable event 
Carrying out prospective analysis when new technology is 
introduced 
